Professor of Medicine, UCSF
Internal Medicine
Dr. Margaret A. Tempero, MD
|
|
Give Review
Margaret Tempero is an expert in the field of Internal Medicine. She went to University of Nebraska Medical Center. University of Nebraska Medical Center is a one of the best medicals schools. University of Nebraska Medical Center is ranked 60/4 in Research/PrimaryCare. She over the years received 5 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Fellow (FASCO)" and "Super Doctor". Doctor Margaret A. Tempero, MD is a published MD. She published 27 publications, including: 'HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer.' She accepts Medicare payments and is listed with Medicare.gov.
Publications
- HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic Cancer.
- Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?: A Pooled Analysis of Phase II Trials of Gemcitabine-Containing...
- A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal Cancer.
- A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic Cancer.
- Therapeutic advances in pancreatic Cancer.
- Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer.
- A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic Cancer.
- Monoclonal antibodies and other targeted therapies for pancreatic Cancer.
- Optimizing the Administration of Fixed-Dose Rate Gemcitabine Plus Capecitabine Using an Alternating-week Schedule: A Dose Finding and Early Efficacy Study in Advanced ...
- Subtypes of pancreatic Ductal adenocarcinoma and their differing responses to therapy.
- Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancr...
- Personalized medicine for pancreatic Cancer: a step in the right direction.
- A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic Cancer: is an anti-VEGF strate...
- Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic Cancer receiving chemotherapy.
- Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic Cancer: results of a phase II study.
- How I treat pancreatic Ductal adenocarcinoma.
- A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic Cancer.
- Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
- Pancreatic Cancer in mice and man: the Penn Workshop 2004.
- Systemic therapy for pancreatic Cancer.
- Treatment of metastatic pancreatic Cancer.
- Clinical oncology 2004: the president's report.
- Cancer and Leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
- Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a.
- Current and future strategies for combined-modality therapy in pancreatic Cancer.
- Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice.
Schools
University Of Nebraska College Of Medicine
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Fellow (FASCO)
- Super Doctor
Education
-
University of Nebraska Medical Center -
University of Nebraska College of Medicine
Hospital
-
San Francisco General Hospital and Trauma Center -
San Francisco VA Medical Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1225095730 | |
| NPPES Provider LastName | TEMPERO | |
| NPPES Provider FirstName | MARGARET | |
| NPPES Provider ZIPCode | 941153010 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 270.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 40.0 | |
| Percent Opioid Claims | 14.81 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225095730 |
| Last Name Of The Provider | TEMPERO |
| First Name Of The Provider | MARGARET |
| View All |
Similar Doctors
|
Dr. Justin P. Quock, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Claire K. Horton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark A. Herman, MD |
|
|
Dr. Jan C. Hofmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence W. White, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barbara E. Epremian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher C. Benz, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mitchell M. Adachi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karin L. Gaensler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barbara G. Jensen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann K. Lanzerotti, MD |
|
|
Dr. Marianna Kong, MD |
|
|
Dr. Ru-Amir Walker, MD |
|
|
Dr. Michael J. Nystrom, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephanie J. Jeske, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judy M. Cheng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Trever G. Bivona, MD |
|
|
Dr. Andrei Goga, MD
This Doctor is OpenDoctor Recommended.
|